CN100396283C - Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 - Google Patents

Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 Download PDF

Info

Publication number
CN100396283C
CN100396283C CNB018149243A CN01814924A CN100396283C CN 100396283 C CN100396283 C CN 100396283C CN B018149243 A CNB018149243 A CN B018149243A CN 01814924 A CN01814924 A CN 01814924A CN 100396283 C CN100396283 C CN 100396283C
Authority
CN
China
Prior art keywords
alkyl
aryl
group
perhaps
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018149243A
Other languages
English (en)
Chinese (zh)
Other versions
CN1599612A (zh
Inventor
P·D·范佩尔耶
M·D·埃里安
藤原俊彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Metabasis Therapeutics Inc
Original Assignee
Sankyo Co Ltd
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd, Metabasis Therapeutics Inc filed Critical Sankyo Co Ltd
Publication of CN1599612A publication Critical patent/CN1599612A/zh
Application granted granted Critical
Publication of CN100396283C publication Critical patent/CN100396283C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB018149243A 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病 Expired - Fee Related CN100396283C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21653100P 2000-07-06 2000-07-06
US60/216,531 2000-07-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA200810098112XA Division CN101301294A (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病

Publications (2)

Publication Number Publication Date
CN1599612A CN1599612A (zh) 2005-03-23
CN100396283C true CN100396283C (zh) 2008-06-25

Family

ID=22807416

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018149243A Expired - Fee Related CN100396283C (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
CNA200810098112XA Pending CN101301294A (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA200810098112XA Pending CN101301294A (zh) 2000-07-06 2001-07-05 Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病

Country Status (18)

Country Link
EP (1) EP1372660A2 (ru)
JP (1) JP2004508297A (ru)
KR (1) KR100854851B1 (ru)
CN (2) CN100396283C (ru)
AU (2) AU2001273271B2 (ru)
BR (1) BR0112212A (ru)
CA (1) CA2412142A1 (ru)
CZ (1) CZ20035A3 (ru)
HU (1) HUP0301830A3 (ru)
IL (2) IL153513A0 (ru)
MX (1) MXPA02012713A (ru)
NO (1) NO20030034L (ru)
NZ (1) NZ523227A (ru)
PL (1) PL365779A1 (ru)
RU (1) RU2328308C2 (ru)
SK (1) SK62003A3 (ru)
WO (1) WO2002003978A2 (ru)
ZA (1) ZA200300044B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831437A (zh) * 2016-02-03 2017-06-13 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6452098A (en) 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
JP2002524463A (ja) 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
AU2001245532B2 (en) 2000-03-08 2005-08-11 Metabasis Therapeutics, Inc. Novel aryl fructose-1,6-bisphosphatase inhibitors
NZ532427A (en) 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
AU2003201998C1 (en) 2002-01-10 2012-10-25 Imperial Innovations Limited Modification of feeding behavior
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EA013249B1 (ru) 2003-12-26 2010-04-30 Киова Хакко Кирин Ко., Лтд. Производные тиазола
US20070225259A1 (en) * 2004-08-18 2007-09-27 Qun Dang Novel Thiazole Inhibitors of Fructose 1,6-Bishosphatase
TW200633720A (en) * 2004-12-13 2006-10-01 Sankyo Co Medicinal composition for diabetic
TW200738245A (en) * 2005-08-22 2007-10-16 Sankyo Co Pharmaceutical composition containing FBPase inhibitor
WO2007129522A1 (ja) * 2006-04-10 2007-11-15 Daiichi Sankyo Company, Limited 乾式製造法製剤
US20100222304A1 (en) 2006-11-02 2010-09-02 Lillian W Chiang Methods of Treating Neuropathic Pain by Modulation of Glycogenolysis or Glycolysis
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
UY35065A (es) * 2012-10-08 2014-05-30 Lg Life Sciences Ltd Fármaco combinado que comprende gemigliptina y metformina y método para su preparación
CN104788350A (zh) * 2014-01-22 2015-07-22 天津大学 一种通过快速冷却结晶法获得甲糖宁药用优势晶型的方法
CN114907285B (zh) * 2021-02-10 2023-09-22 华中师范大学 酰化糖精类化合物及其制备方法和应用、降血糖药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
CN1400908A (zh) * 2000-01-21 2003-03-05 诺瓦提斯公司 含有二肽基肽酶－iv抑制剂的联合形式

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2008325A1 (en) * 1989-01-24 1990-07-24 Harry E. Gruber Method and compounds for aica riboside delivery and for lowering blood glucose
AU6452098A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel purine inhibitors of fructose-1,6-bisphosphatase
PT970095E (pt) * 1997-03-07 2004-03-31 Metabasis Therapeutics Inc Novos inibidores benzimidazole de frutose-1,6-bisfosfatase
AU6691798A (en) * 1997-03-07 1998-09-22 Metabasis Therapeutics, Inc. Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase
JP2002524463A (ja) * 1998-09-09 2002-08-06 メタバシス・セラピューティクス・インコーポレイテッド フルクトース−１，６−ビスホスファターゼの新規な芳香族インヒビター
CN101164618A (zh) * 1998-12-24 2008-04-23 症变治疗公司 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
GB0015627D0 (en) * 2000-06-26 2000-08-16 Rademacher Group Limited Phosphoglycan messengers and their medical uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
CN1400908A (zh) * 2000-01-21 2003-03-05 诺瓦提斯公司 含有二肽基肽酶－iv抑制剂的联合形式

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106831437A (zh) * 2016-02-03 2017-06-13 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用
CN106831437B (zh) * 2016-02-03 2019-06-21 华中师范大学 含硝基乙烯基的酯类化合物及其制备方法和应用

Also Published As

Publication number Publication date
CN1599612A (zh) 2005-03-23
HUP0301830A2 (hu) 2003-11-28
CA2412142A1 (en) 2002-01-17
BR0112212A (pt) 2003-12-30
IL153513A0 (en) 2003-07-06
NO20030034D0 (no) 2003-01-03
ZA200300044B (en) 2004-05-06
KR20030031952A (ko) 2003-04-23
RU2328308C2 (ru) 2008-07-10
AU7327101A (en) 2002-01-21
CZ20035A3 (cs) 2003-05-14
NO20030034L (no) 2003-03-05
PL365779A1 (en) 2005-01-10
WO2002003978A2 (en) 2002-01-17
WO2002003978A3 (en) 2003-10-16
NZ523227A (en) 2005-04-29
AU2001273271B2 (en) 2006-01-05
JP2004508297A (ja) 2004-03-18
SK62003A3 (en) 2003-09-11
HUP0301830A3 (en) 2007-10-29
EP1372660A2 (en) 2004-01-02
IL153513A (en) 2014-07-31
MXPA02012713A (es) 2004-09-10
KR100854851B1 (ko) 2008-08-27
CN101301294A (zh) 2008-11-12

Similar Documents

Publication Publication Date Title
CN100396283C (zh) Fbp酶抑制剂与抗糖尿病药联合用于治疗糖尿病
US20090197836A1 (en) Combination of FBPase Inhibitors and Antidiabetic Agents Useful for the Treatment of Diabetes
CN100352505C (zh) 治疗糖尿病的fbp酶抑制剂与胰岛素致敏剂的组合
US20080004226A1 (en) Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes
Aboul-Enein et al. Benzimidazole derivatives as antidiabetic agents
JPH06184116A (ja) 医薬組成物
AU2001273271A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
SK8892002A3 (en) Novel bisamidate phosphonate prodrugs, process for their preparation and use thereof
CA2344309A1 (en) Method for treating diabetes employing an ap2 inhibitor and combination
JPH11302177A (ja) 腎炎治療剤
AU2006265653A1 (en) Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer
NZ523189A (en) Benzodiazepine (BZP) receptor inverse agonists for the prevention and treatment of alzheimer's disease and schizophrenia
AU2006201410A1 (en) A combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: METABASIS THERAPEUTICS INC.

Free format text: FORMER OWNER: METABASIS THERAPEUTICS INC.; FIRST SANKYO CO., LTD.

Effective date: 20080704

Owner name: METABASIS THERAPEUTICS INC.; FIRST SANKYO CO., LT

Free format text: FORMER OWNER: METABASIS THERAPEUTICS INC.; SANKYO CO., LTD.

Effective date: 20080704

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20080704

Address after: California, USA

Patentee after: METABASIS THERAPEUTICS, Inc.

Address before: California, USA

Co-patentee before: DAIICHI SANKYO Co.,Ltd.

Patentee before: METABASIS THERAPEUTICS, Inc.

Effective date of registration: 20080704

Address after: California, USA

Co-patentee after: DAIICHI SANKYO Co.,Ltd.

Patentee after: METABASIS THERAPEUTICS, Inc.

Address before: California, USA

Co-patentee before: Sankyo Co.,Ltd.

Patentee before: METABASIS THERAPEUTICS, Inc.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080625

Termination date: 20180705